Standard strategies for diagnosis and treatment of patients with newly diagnosed Parkinson disease
FRANCE
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In France, newly diagnosed patients with Parkinson disease (PD) are mostly referred by a general practitioner (GP) to a public (hospital-based) or private practice neurologist for confirmation of the diagnosis and treatment initiation. Most neurologists rely on a clinical evaluation according to National Health Authority (HAS) recommendations and guidelines.1 MRI scans and dopamine transporter imaging are increasingly being performed for the differential diagnosis of atypical parkinsonism, for drug-induced parkinsonism and tremor, in early-onset patients, or to deal with the anxiety of patients and their families. Clinical scales such as the Unified Parkinson's Disease Rating Scale are scarcely used in routine practice. Therapeutic strategies are not or little affected by who is covering the cost of treatment or by how medical facilities and professionals are reimbursed, ensuring that health care guidelines are usually respected. Indeed, the expenses for drugs and other inpatient and ambulatory health care are almost fully covered by the health insurance within the frame of chronic diseases (“Affection de longue durée n°16”), providing that the parkinsonian syndrome is irreversible and requires the administration of antiparkinsonian drugs for at least 6 months. Some newly diagnosed patients, before being registered by the free care system for chronic diseases, may only have partial coverage of costs (65%). However, most of them have complementary private insurance allowing full reimbursement of their expenses.
Footnotes
Study funding: No targeted funding reported.
Disclosures: F. Tison has served on scientific advisory boards for Novartis, UCB, Boehringer-Ingelheim, GlaxoSmithKline, and ABBOTT; has received funding for travel from GlaxoSmithKline, Lundbeck, Novartis, TEVA, and UCB; serves as a consultant for ADDEX Pharma; and receives research support from Novartis, the French Ministry of Health, the University Hospital Bordeaux, and the Michael J. Fox Foundation. W. G. Meissner has served on scientific advisory boards for ANM GmbH and Novartis; has served on speakers bureaus for and received funding for travel and/or speaker honoraria from GSK, Expression Santé, Lundbeck, Novartis, TEVA, and UCB; serves on the editorial board of the Journal of Neural Transmission; and has received research funding from the Michael J. Fox Foundation, the University Hospital Bordeaux, the French Health Ministry, APTES (French patient association for essential tremor), and PSP-France, as well as unrestricted research grants from Novartis and TEVA/Lundbeck. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
The Nerve!: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Zonisamide improves motor function in Parkinson diseaseA randomized, double-blind studyMiho Murata, Kazuko Hasegawa, Ichiro Kanazawa et al.Neurology, January 02, 2007 -
Articles
Extended-release pramipexole in early Parkinson diseaseA 33-week randomized controlled trialW. Poewe, O. Rascol, P. Barone et al.Neurology, August 10, 2011 -
Articles
Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's diseaseMark Guttman, International Pramipexole-Bromocriptine Study Group et al.Neurology, October 01, 1997 -
COMT Inhibition for the Treatment of Parkinson's Disease: Articles
Tolcapone in stable Parkinson's diseaseEfficacy and safety of long-term treatmentC. H. Waters, M. Kurth, P. Bailey et al.Neurology, May 01, 1998